Article Text

PDF
Clinical insights into paraneoplastic cerebellar degeneration
  1. R Scheid1,
  2. R Voltz2,
  3. S Briest3,
  4. R Kluge4,
  5. D Y von Cramon1
  1. 1Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, and Day Clinic of Cognitive Neurology, University of Leipzig, Germany
  2. 2Department of Palliative Medicine, University of Cologne, Cologne, Germany
  3. 3Department of Gynaecology, University of Leipzig
  4. 4Department of Nuclear Medicine, University of Leipzig
  1. Correspondence to:
 Dr Rainer Scheid
 Day Clinic of Cognitive Neurology, University of Leipzig, Liebigstr 22a, 04103 Leipzig, Germany; scheid{at}cbs.mpg.de

Abstract

Neuroimaging is usually unremarkable in paraneoplastic cerebellar degeneration (PCD), at least in the early stages of the disease. A patient with proven PCD is reported in whom it could be shown that cerebellar atrophy evolved very rapidly and was present in early imaging studies. Even with the use of the whole spectrum of modern diagnostic tools, the underlying malignancy can be difficult to diagnose. In addition to mammography, MRI is recommended in these cases and repeat FDG-PET may be necessary.

  • FDG, fluorodeoxyglucose
  • PCD, paraneoplastic cerebellar degeneration
  • cerebellar atrophy
  • FDG-PET
  • MRI
  • paraneoplastic cerebellar degeneration

Statistics from Altmetric.com

Footnotes

  • Competing interests: none declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles